1.
Prognostic and clinicopathological significance of LOXL2 in cancers: A systematic review and meta-analysis.
Zhang, X, Huang, J, You, F, Li, W, Zou, Z
Journal of cellular physiology. 2019;(11):21369-21379
Abstract
BACKGROUND Lysyl oxidase-like 2 (LOXL2) is an extracellular matrix (ECM)-modifying enzyme which can regulate the tensile strength of connective tissues by crosslink of collagen and elastin. Numerous studies have claimed correlations between LOXL2 expression and prognosis or clinicopathological characteristics in various cancers. However, the validities of these claims are still in question. To address these experimental results, a meta-analysis was done to assess the prognostic and clinicopathological significance of LOXL2 expression in various cancers. METHODS The keywords were used for searching systematically in PubMed, Web of Science, Embase, Wanfang database, and CNKI. Stata SE15.0 was used for meta-analysis. The hazard ratio (HR) and odds ratios (ORs) were pooled to assess the relationship between LOXL2 expression and overall survival (OS), disease-free survival (DFS), and clinicopathological parameters. RESULTS Seventeen studies with 3,881 patients were considered as valid studies. The results indicated that the patients who had a positive LOXL2 expression had a shorter OS (HR 1.60, 95% CI 1.26-1.94, p < 0.001) or DFS (HR 1.46, 95% CI 1.14-1.78, p < 0.001). For clinicopathological parameters, statistical significances were presented in age (OR 1.34, 95% CI 1.13-1.58, p = 0.001), lymph node metastasis (OR 2.20, 95% CI 1.37-3.53, p < 0.001), tumor size (OR 1.46, 95% CI 1.15-1.85, p = 0.002), and vascular invasion (OR 1.82, 95% CI 1.33-2.48, p < 0.001). CONCLUSIONS The results demonstrate that positive LOXL2 expression presents poorer OS and worse clinicopathological parameters. LOXL2 may be an effective biomarker to evaluate the prognosis in different type of cancers.
2.
Value of folate receptor-positive circulating tumour cells in the clinical management of indeterminate lung nodules: A non-invasive biomarker for predicting malignancy and tumour invasiveness.
Zhou, Q, Geng, Q, Wang, L, Huang, J, Liao, M, Li, Y, Ding, Z, Yang, S, Zhao, H, Shen, Q, et al
EBioMedicine. 2019;:236-243
Abstract
BACKGROUND Non-invasive lung adenocarcinoma could benefit from limited resection, nonetheless, there is a lack of method to determine preoperative tumour invasiveness. We aimed to investigate whether folate receptor-positive circulating tumour cells (FR+-CTCs) in combination with maximum tumour diameter (MTD) determines, before surgery, the invasiveness of small-sized, indeterminate solitary pulmonary nodules (SPNs). METHODS A total of 382 patients with suspicious lung adenocarcinoma on computed tomography who were expected to undergo lung resection were enrolled in this study at three participating institutes and randomly assigned into training and validation cohorts. Before surgery, 3 mL peripheral blood was collected from all participants. FR+-CTCs were analyzed using immunomagnetic leukocyte depletion and quantitated by ligand-targeted PCR method. After surgery, the resected tissues were diagnosed by pathologists according to IASLC/ATS/ERS classification. FINDINGS FR+-CTC levels in the peripheral blood can differentiate benign from malignant nodules with a sensitivity of 78·6%-82·7% and a specificity of 68·8%-78·4%. Both FR+-CTC and MTD are independent predictive indices of invasive tumours for lung adenocarcinoma ≤2 cm based on multivariate analyses. Further, FR+-CTC count in combination with MTD can differentiate non-invasive cancers from invasive cancers with a sensitivity of 63·6%-81·8% and a specificity of 71·4%-89·7%. INTERPRETATION Detection of FR+-CTC is a reliable method to differentiate malignancy of indeterminate SPNs. Combining of FR+-CTC count and MTD could possibly enhance preoperative determination of the invasiveness of lung nodules and guide surgeons to select limited lung resection and avoid overtreatment for patients with non-invasive lesions. FUND None.
3.
Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou, Y, Suo, S, Tong, H, Ye, X, Wang, Y, Chen, Z, Qian, W, Meng, H, Mai, W, Huang, J, et al
Leukemia research. 2013;(11):1451-6
Abstract
Currently, there are few studies that address the prognostic significance of baseline additional chromosomal abnormalities (ACAs) in newly diagnosed acute promyelocytic leukemia (APL) patients treated with arsenic trioxide (ATO) as the front-line therapy. A series of 271 consecutive APL patients has been cytogenetically investigated between 2004 and 2011 in our institution. The incidence of ACAs was 27% (46/172) in APL cases with t(15;17). Trisomy 8 was the most recurrent abnormality, accounting for 30% (14/46) of patients with ACAs, followed by +21 (7%, 3/46) and -7/7q (7%, 3/46). Nine cases (14.1%) were found to have additional balanced translocation aberrations, most of them are new and non-recurrent. Treatment protocols consisted of all-trans retinoic acid (ATRA) and chemotherapy with or without the ATO therapy. Overall, patients with and without ACAs had similar complete remission (CR) rates (94% and 98%, respectively, P=0.344). With a median follow-up of 41 months, univariate analysis showed that ACAs did not show any prognostic significance in relapse-free survival (RFS) and overall survival (OS). In addition, ATO treatment was an independent favorable predictor for RFS. Thus, this data provides insights into cytogenetic features of APL, and suggests that ATO-based combination therapy improved RFS in de novo APL patients, while ACAs had no impact on prognosis.